Evidence map›Paper›PMID 31142441›Full record

Trial reportKidney international2019

Analysis from the EMPA-REG OUTCOME

Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07547878 (A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes), which is not on this map. Cited by 49 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07547878 phase4not yet recruitingstarted 2026, after this paper: background citation

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Ran2026Enrolled64Registered outcomes18Posted comparisons0ConditionsChronic Kidney Disease, Type 2 DiabetesArmsAccupril, Aceon, Altace, Atacand, Avapro
PMID 34423370PMID 38785209PMID 37952217PMID 18362259PMID 14531770PMID 20853156PMID 22169081PMID 26264780PMID 28597606PMID 28828479PMID 31146814PMID 33580784other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Review
  12. Article
  13. Article
  14. Review
  15. Gliflozins in hypertension: basic mechanisms and clinical insights.American journal of physiology. Renal physiology · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Gert J MayerDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University, Innsbruck, Austria.
Christoph WannerDivision of Nephrology, Würzburg University Clinic, Würzburg, Germany.
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Silvio E InzucchiSection of Endocrinology, Yale School of Medicine, New Haven, Connecticut, USA.
Audrey Koitka-WeberDivision of Nephrology, Würzburg University Clinic, Würzburg, Germany; Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Stefan HantelBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Maximilian von EynattenBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
David Z I CherneyDepartment of Medicine and Department of Physiology, Division of Nephrology, University Health Network, University of Toronto, Canada. Electronic address: david.cherney@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel blockers (CCBs) and diuretics. Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used by some individuals. In this exploratory, non-prespecified analysis, we investigated whether the kidney benefits of EMPA are altered in individuals already using the medications in these categories. In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME

Indexed as

AdultAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsCalcium Channel BlockersCardiovascular DiseasesComorbidityDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDiureticsFemaleGlomerular Filtration RateGlucosidesHumansKidneyAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsCalcium Channel BlockersDiureticsempagliflozinGlucosidesProtective AgentsSodium-Glucose Transporter 2 InhibitorsACEisCKDCV diseasediureticssodium-glucose cotransporter 2 inhibitorstype 2 diabetes

Identifiers

PMID31142441

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.